DUBLIN--(BUSINESS WIRE)--The "Diabetic Retinopathy - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Diabetic Retinopathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 9, 13, 5, 72, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 2 molecules, respectively.
Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)
Key Topics Covered:
Introduction
Diabetic Retinopathy - Overview
Diabetic Retinopathy - Therapeutics Development
Diabetic Retinopathy - Therapeutics Assessment
Diabetic Retinopathy - Companies Involved in Therapeutics Development
Diabetic Retinopathy - Drug Profiles
Diabetic Retinopathy - Dormant Projects
Diabetic Retinopathy - Discontinued Products
Diabetic Retinopathy - Product Development Milestones
Appendix
Companies Mentioned
- 3SBio Inc
- A6 Pharmaceuticals LLC
- Accuitis Pharmaceuticals Inc
- Adverum Biotechnologies Inc
- Aerie Pharmaceuticals Inc
- Afecta Pharmaceuticals Inc
- Akaal Pharma Pty Ltd
- Antisense Therapeutics Ltd
- Apexian Pharmaceuticals Inc
- Applied Therapeutics Inc
- AptaBio Therapeutics Inc
- Aptamer Sciences Inc
- Araim Pharmaceuticals Inc
- Ascentage Pharma Group International
- BetaStem Therapeutics Inc
- Bio-Thera Solutions Ltd
- Boehringer Ingelheim International GmbH
- Bonac Corp
- CCRP Therapeutics GmbH
- Cell Care Therapeutics Inc
- Charlesson LLC
- Clayton Biotechnologies Inc
- Coherus BioSciences Inc
- Curacle Co Ltd
- Dimerix Ltd
- Elasmogen Ltd
- Emerald Bioscience Inc
- Ennovabio
- Epigen Biosciences Inc
- Everglades Biopharma LLC
- Excitant Therapeutics LLC
- EyeGene Inc
- EyePoint Pharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- Foresee Pharmaceuticals Co Ltd
- Generium
- Glycadia Inc
- Graybug Vision Inc
- Guangzhou Magpie Pharmaceutical Co Ltd
- HanAll Biopharma Co Ltd
- Hengenix Biotech Inc
- iVeena Delivery Systems Inc
- Kalos Therapeutics Inc
- Kanaph Therapeutics Inc
- Kato Pharmaceuticals Inc
- Kodiak Sciences Inc
- Kowa Co Ltd
- Kubota Vision Inc
- Kuur Therapeutics Ltd
- Lupin Ltd
- Luye Pharma Group Ltd
- Mabion SA
- MingSight Pharmaceuticals Inc
- Mirae Cell Bio Co Ltd
- Mirrx Therapeutics A/S
- Nanoscope Therapeutics Inc
- NeuMedics Inc
- Neurodegeneration Therapeutics Inc
- NGM Biopharmaceuticals Inc
- Novago Therapeutics AG
- Novartis AG
- Novelty Nobility Inc
- Noveome Biotherapeutics Inc
- OccuRx Pty Ltd
- Ocugen Inc
- OcuNexus Therapeutics Inc
- OliPass Corporation
- Opera Therapeutics
- Oxurion NV
- Palatin Technologies Inc
- Panoptes Pharma GesmbH
- Phanes Therapeutics Inc
- PharmAbcine Inc
- Pinotbio Inc
- Profarma
- Protheragen Inc
- PYCTX Ltd
- Regeneron Pharmaceuticals Inc
- RegenxBio Inc
- Retinset SL
- Retrotope Inc
- Reven Pharmaceuticals Inc
- Rezolute Inc
- Ribomic Inc
- Serodus ASA
- Singh Biotechnology LLC
- SiNOPSEE Therapeutics Pte Ltd
- Skyran Biologics Inc
- SmartinBio
- Stealth BioTherapeutics Corp
- SunBio Inc
- Sylentis SAU
- Teraclon IDF SL
- Topadur Pharma AG
- Translatum Medicus Inc
- USA Elixiria Biotech Inc
- Valitor Inc
- VESSL Therapeutics Ltd
- Vitreo Pharma Inc
- Wntgen LLC
- Xbrane Biopharma AB
- YD Life Science Co
- Zih Yuan Tang Biotechnology Co Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dglqk6
